Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

A Randomized Trial to Compare the Efficacy and Safety of Antiemetic Treatment with Ondansetron and Ondansetron Zydis in Patients with Breast Cancer Treated with High-dose Epirubicin

D. PECTASIDES, U. DAFNI, G. ARAVANTINOS, E. TIMOTHEADOU, D.V. SKARLOS, N. PAVLIDIS, A. GAGLIA, H.P. KALOFONOS and G. FOUNTZILAS
Anticancer Research November 2007, 27 (6C) 4411-4417;
D. PECTASIDES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pectasid@otenet.gr
U. DAFNI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. ARAVANTINOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. TIMOTHEADOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D.V. SKARLOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. PAVLIDIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. GAGLIA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.P. KALOFONOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. FOUNTZILAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Objective: The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast cancer patients. Patients and Methods: A total of 134 breast cancer patients receiving high-dose epirubicin participated in a randomized trial comparing the antiemetic efficacy and safety of an 8 mg OT given twice daily to an 8 mg orally ODT given twice daily, both for 3 days. Results: OT was significantly better in the complete control of emesis (72% versus 52%, p=0.020) and marginally better in the complete control of nausea (66% versus 48%, p=0.054) induced by high-dose epirubicin over days 1-3 compared to ODT. However, no differences were found in major control of emesis (0 to 2 emetic episodes, 76% versus 70%, p=0.28) over days 1-3. Conclusion: OT was significantly better in the complete control of emesis and marginally better in the complete control of nausea, but not in the major control of emesis and nausea induced by high-dose epirubicin compared to ODT. ODT may be an effective alternative to OT, particularly in patients who have difficulties in swallowing a conventional tablet.

  • Ondansetron
  • orally disintegrating tablet
  • emesis
  • nausea
  • epirubicin
  • breast cancer

Footnotes

  • Received June 20, 2007.
  • Revision received September 11, 2007.
  • Accepted October 8, 2007.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 27 (6C)
Anticancer Research
Vol. 27, Issue 6C
November-December 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Randomized Trial to Compare the Efficacy and Safety of Antiemetic Treatment with Ondansetron and Ondansetron Zydis in Patients with Breast Cancer Treated with High-dose Epirubicin
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A Randomized Trial to Compare the Efficacy and Safety of Antiemetic Treatment with Ondansetron and Ondansetron Zydis in Patients with Breast Cancer Treated with High-dose Epirubicin
D. PECTASIDES, U. DAFNI, G. ARAVANTINOS, E. TIMOTHEADOU, D.V. SKARLOS, N. PAVLIDIS, A. GAGLIA, H.P. KALOFONOS, G. FOUNTZILAS
Anticancer Research Nov 2007, 27 (6C) 4411-4417;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A Randomized Trial to Compare the Efficacy and Safety of Antiemetic Treatment with Ondansetron and Ondansetron Zydis in Patients with Breast Cancer Treated with High-dose Epirubicin
D. PECTASIDES, U. DAFNI, G. ARAVANTINOS, E. TIMOTHEADOU, D.V. SKARLOS, N. PAVLIDIS, A. GAGLIA, H.P. KALOFONOS, G. FOUNTZILAS
Anticancer Research Nov 2007, 27 (6C) 4411-4417;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
  • Google Scholar

More in this TOC Section

  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire